Skip to main content

Table 5 Treatment-Emergent Cardiovascular Adverse Events in Patients with Cardiovascular Risk Factors at Baseline

From: Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies

  Eptinezumab 100 mg Eptinezumab 300 mg Eptinezumab 1000 mg Placebo
Patients with at least 1 cardiovascular risk factor, n (%) N = 350 N = 316 N = 41 N = 382
Any TEAE 196 (56.0) 187 (59.2) 22 (53.7) 220 (57.6)
Cardiac or Vascular TEAEs 13 (3.7) 14 (4.4) 4 (9.8) 19 (5.0)
 Increased blood pressure 5 (1.4) 3 (0.9) 0 2 (0.5)
 Hypertension 2 (0.6) 1 (0.3) 0 5 (1.3)
 Hot flush 0 3 (0.9) 0 0
 Palpitations 1 (0.3) 1 (0.3) 0 3 (0.8)
 Syncope 2 (0.6) 2 (0.6) 0 3 (0.8)
 Tachycardia 0 2 (0.6) 0 1 (0.3)
 Chest pain 0 0 1 (2.4) 1 (0.3)
 ECG QT prolongation 0 0 2 (4.9) 1 (0.3)
 Flushing 0 1 (0.3) 0 1 (0.3)
 Sinus tachycardia 1 (0.3) 0 0 0
 Increased systolic blood pressure 1 (0.3) 0 0 0
 Abnormal ECG Q wave 0 0 1 (2.4) 0
 Increased heart rate 0 1 (0.3) 0 0
 Hypotension 1 (0.3) 0 0 0
 Atrial fibrillation 0 0 0 1 (0.3)
 Prehypertension 0 0 0 1 (0.3)
Patients with at least 2 cardiovascular risk factors, n (%) N = 97 N = 83 N = 7 N = 112
Any TEAE 54 (55.7) 51 (61.4) 4 (57.1) 69 (61.6)
Cardiac or Vascular TEAEs 8 (8.2) 4 (4.8) 0 8 (7.1)
 Increased blood pressure 2 (2.1) 1 (1.2) 0 1 (0.9)
 Hypertension 2 (2.1) 1 (1.2) 0 4 (3.6)
 Syncope 2 (2.1) 1 (1.2) 0 2 (1.8)
 Palpitations 1 (1.0) 0 0 0
 Hot flush 0 1 (1.2) 0 0
 Sinus tachycardia 1 (1.0) 0 0 0
 Atrial fibrillation 0 0 0 1 (0.9)
  1. ECG Electrocardiogram, TEAE Treatment-emergent adverse event